Phenotypic Ultra-Rapid Antimicrobial Susceptibility Testing for Ceftazidime–Avibactam: In Support of Antimicrobial Stewardship
Ceftazidime–avibactam (CZA) is a potent broad-spectrum drug combination covering extended-spectrum β-lactamases, AmpC, and carbapenemases of class A and D, OXA-48-type producers. Rapid antimicrobial susceptibility testing is crucial for the timely de-escalation/escalation of therapy. We evaluate CZA...
Saved in:
| Main Authors: | Inês Martins-Oliveira, Blanca Pérez-Viso, Rosário Gomes, David Abreu, Ana Silva-Dias, Rafael Cantón, Cidália Pina-Vaz |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Microorganisms |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2607/13/2/414 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Characteristics of Patients Who Acquired Gram-Negative Bacteria During Ceftazidime-Avibactam Therapy
by: Chien Chuang, et al.
Published: (2025-04-01) -
The Impact Of Ceftazidime-Avibactam Utilization In Hospital Setting
by: Shobana Selvaganesan, et al.
Published: (2024-12-01) -
Risk factors for mortality in patients treated with ceftazidime-avibactam for ceftazidime-avibactam susceptible carbapenem-resistant Klebsiella pneumoniae bacteremia
by: Yi-Tsung Lin, et al.
Published: (2025-09-01) -
In Vitro Efficacy of Ceftazidime-avibactam Against blaOXA-48-producing Klebsiella pneumoniae Isolates
by: Yasemin ÇAĞ, et al.
Published: (2023-11-01) -
In vitro activity of aztreonam–avibactam combination against blood culture isolates of Stenotrophomonas maltophilia in Japan before the launch of ceftazidime–avibactam
by: Wataru Aoki, et al.
Published: (2025-05-01)